A study published this week in The Lancet Infectious Diseases highlights the substantial impact of infectious diseases on global health.

A new study by researchers with the Centers for Disease Control and Prevention and Harvard T.H. Chan School of Public Health has found significant and persistent racial disparities in tuberculosis (TB) incidence among US-born residents. The findings were published yesterday in the Annals of Internal Medicine.

Global tuberculosis (TB) incidence, mortality, and disability-adjusted life years (DALYs) have decreased significantly in adolescents and young adults since 1990, but the incidence of drug-resistant TB increased, Chinese researchers reported in Pediatrics.

A survey of national tuberculosis (TB) program staff members projects consistent global growth in the use of shorter, all-oral drug regimens for drug-resistant TB (DR-TB), but national efforts to ensure the new treatments are accessible to eligible patients are needed, researchers reported late last week in PLOS One.

A study of tuberculosis (TB) patients in South Africa found that more than half receiving treatment with a bedaquiline-containing regimen had isolates with bedaquiline resistance, researchers reported in The Lancet Microbe.

In a study that could have an impact on the treatment of drug-resistant tuberculosis (TB), a team of South African researchers report that the novel TB drug bedaquiline was associated with a significant reduction in mortality for patients with multidrug-resistant (MDR), rifampicin-resistant, and extensively drug-resistant (XDR) strains of the infection.